Key result
Leukocyte-derived microparticles were independently associated with subclinical atherosclerosis burden (2- to 3-sites disease) in asymptomatic subjects (P<0.05).
Why the study?
Are circulating leukocyte-derived microparticles associated with subclinical atherosclerosis burden in asymptomatic subjects without cardiovascular disease?
Cross-Sectional (n=216)
Are circulating leukocyte-derived microparticles associated with subclinical atherosclerosis burden in asymptomatic subjects without cardiovascular disease?
p-value: p=<0.05
Leukocyte-derived microparticles are independently associated with subclinical atherosclerosis burden in asymptomatic individuals, suggesting a potential novel biomarker for preclinical disease.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice; hypothesis-generating for microparticles as atherosclerosis biomarkers, needing prospective validation.
Chironi et al. (2006) conducted a cross-sectional in Subclinical atherosclerosis (n=216). Leukocyte-derived microparticles vs. Lower levels of leukocyte-derived microparticles was evaluated on Subclinical atherosclerosis burden (2- to 3-sites disease) (p=<0.05). Leukocyte-derived microparticles were independently associated with subclinical atherosclerosis burden (2- to 3-sites disease) in asymptomatic subjects (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: